HPV Infection Clinical Trial
Official title:
Characteristics of Vaginal and Intestinal Microbiota in Women With Different Cervical HPV Infection
Verified date | November 2023 |
Source | Fujian Maternity and Child Health Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
There are different microbial communities on the surface of human body (skin, hair, nails, etc.) and in the cavity connected with the outside world. The human microbiota is the general term of the genetic information of microorganisms that coexist with human beings and cause various diseases under certain conditions. The results of human microbial genome analysis show that the microbial communities in different parts of the human body and different individuals have amazing diversity, some of which play an important role in human health, and some are closely related to diseases. Female lower genital tract infection is often associated with human papillomavirus (HPV) infection and bacterial vaginosis (BV), such as cervical and vaginal precancerous lesions, cancer, condyloma acuminatum and other sexually transmitted diseases (STD). Persistent infection of high-risk human papillomavirus (HR-HPV) is closely related to the occurrence of invasive cervical cancer. New evidence suggests that vaginal microbiota composition is different in women with HR-HPV infection and high-grade cervical lesions. The increase of the severity of cervical intraepithelial neoplasia is related to the decrease of the relative abundance of vaginal Lactobacillus. In addition to vaginal microbes, the powerful intestinal flora is considered to be the "invisible organ" of the human body. There is a dynamic and balanced interaction network between intestinal microorganisms and human immune cells. Once the intestinal flora is out of balance, the changes in species, quantity, proportion, location and biological characteristics will cause a series of inflammatory reactions and immune system diseases, and even lead to cancer. Some studies have shown that there is a potential relationship between intestinal microorganisms and vaginal microorganisms. Recent research evidence suggests that the mutually beneficial relationship between oral bacteria and other vaginal bacteria supports the colonization of pathogens and may help maintain the characteristics of vaginal flora imbalance.
Status | Active, not recruiting |
Enrollment | 651 |
Est. completion date | May 31, 2024 |
Est. primary completion date | May 31, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 20 Years to 65 Years |
Eligibility | Inclusion Criteria: - Women aged 20-65. - TCT examination was performed in the last 3 months with abnormal results. - Non pregnant people with sexual history. - Asexual life, no vaginal medication or flushing before 72 hours of sampling. Exclusion Criteria: - Within 8 weeks after pregnancy or postpartum. - Patients with history of genital tract tumor. - History of HPV vaccination. - Previous history of hysterectomy, cervical surgery, pelvic radiotherapy Historical. - In recent one month, she has received genital tract infection, HPV or other STDs treatment related to the infection of mycoplasma. - Use antibiotics or vaginal microecological improvement products in recent 1 month. |
Country | Name | City | State |
---|---|---|---|
China | Shunde Women's and Children's Hospital of Guangdong Medical University | Foshan | Guangdong |
China | Fujian Maternity and Child Health Hospital | Fuzhou | Fujian |
China | Mindong Hospital of Ningde City | Ningde | Fujian |
China | Quanzhou First Hospital Afflicated to Fujian Medical University | Quanzhou | Fujian |
China | Maternal and Child Health Hospital of Shenzhen Province | Shenzhen | Guangdong |
China | Maternal and Child Health Hospital of Hubei Province | Wuhan | Hubei |
China | Xiamen Maternity and Child Health Hospital Affiliated to Xiamen University | Xiamen | Fujian |
China | Zhangzhou affiliated Hospital of Fujian Medical University | Zhangzhou | Fujian |
Lead Sponsor | Collaborator |
---|---|
Fujian Maternity and Child Health Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cervical histopathology testing at baseline | Cervical histopathology was performed at baseline for all participants. | Baseline | |
Primary | Cervical histopathology testing at 12-month follow-up | Cervical histopathology was performed at 12-month follow-up for cervical HPV infection or cytology abnormalities women. | 12-month follow-up | |
Primary | Cervical histopathology testing at 24-month follow-up | Cervical histopathology was performed at 24-month follow-up for cervical HPV infection or cytology abnormalities women. | 24-month follow-up | |
Primary | Human Papillomavirus (HPV) DNA testing at baseline | All participants were tested for HPV DNA of cervical exfoliated cells at the time of baseline. | baseline | |
Primary | Human Papillomavirus (HPV) DNA testing at 6-month follow-up | All participants were tested for HPV DNA of cervical exfoliated cells at the time of 6-month follow-up. | 6-month follow-up | |
Primary | Human Papillomavirus (HPV) DNA testing at 12-month follow-up | All participants were tested for HPV DNA of cervical exfoliated cells at the time of 12-month follow-up. | 12-month follow-up | |
Primary | Human Papillomavirus (HPV) DNA testing at 24-month follow-up | All participants were tested for HPV DNA of cervical exfoliated cells at the time of 24-month follow-up. | 24-month follow-up | |
Primary | Cervical cytology testing at baseline | All participants were tested for cervical cytology at the time of baseline. | baseline | |
Primary | Sequencing of the vaginal microbiota at baseline | All participants underwent microbiological metagenomic sequencing of vaginal secretions at baseline. | baseline | |
Primary | Sequencing of the vaginal microbiota at 6-month follow-up | All participants underwent microbiological metagenomic sequencing of vaginal secretions at 6-month follow-up. | 6-month follow-up | |
Primary | Sequencing of the vaginal microbiota at 12-month follow-up | All participants underwent microbiological metagenomic sequencing of vaginal secretions at 12-month follow-up. | 12-month follow-up | |
Primary | Sequencing of the vaginal microbiota at 24-month follow-up | All participants underwent microbiological metagenomic sequencing of vaginal secretions at 24-month follow-up. | 24-month follow-up | |
Primary | Sequencing of the gut microbiota at baseline | All participants underwent fecal microbiome sequencing at baseline. | baseline | |
Primary | Sequencing of the gut microbiota at 6-month follow-up | All participants underwent fecal microbiome sequencing at 6-month follow-up. | 6-month follow-up | |
Primary | Sequencing of the gut microbiota at 12-month follow-up | All participants underwent fecal microbiome sequencing at 12-month follow-up. | 12-month follow-up | |
Primary | Untargeted Metabolites of vaginal secretions testing at baseline | All participants were tested for microbial untargeted metabolites of vaginal secretions at baseline by liquid chromatography tandem mass spectrometric (LC-MS). Measure abundances of vaginal secretions metabolites, metabolic networks, and metabolic pathways activity. | baseline | |
Primary | Change in vaginal secretions metabolome from baseline to 12-month follow-up assessments | All participants were tested for microbial metabolites of vaginal secretions at 6-month follow-up and 12-month follow-up by LC-MS. Change in vaginal secretions metabolome from baseline to 12-month follow-up were assessed. | 6-month follow-up and 12-month follow-up | |
Primary | Serum metabolites testing at baseline | All participants were tested for serum metabolites at enrollment by LC-MS. Measure abundances of serum metabolites, metabolic networks, and metabolic pathways activity. | baseline | |
Primary | Change in serum metabolome from baseline to 12-month follow-up assessments | All participants were tested for microbial metabolites of serum at 6-month follow-up and 12-month follow-up by LC-MS. Change in serum metabolome from baseline to 12-month follow-up were assessed. | 6-month follow-up and 12-month follow-up | |
Secondary | vaginal cytokine testing at enrollment | All participants were tested for IL-6 (pg/ml), IL-8 (pg/ml), IL-1ß (pg/ml) and other cytokines in vaginal secretions at enrollment. | Enrollment | |
Secondary | vaginal cytokine testing at 6-month follow-up | All participants were tested for IL-6 (pg/ml), IL-8 (pg/ml), IL-1ß (pg/ml) and other cytokines in vaginal secretions at 6-month follow-up. | 6-month follow-up | |
Secondary | vaginal cytokine testing at 12-month follow-up | All participants were tested for IL-6 (pg/ml), IL-8 (pg/ml), IL-1ß (pg/ml) and other cytokines in vaginal secretions at 12-month follow-up. | 12-month follow-up | |
Secondary | vaginal cytokine testing at 24-month follow-up | All participants were tested for IL-6 (pg/ml), IL-8 (pg/ml), IL-1ß (pg/ml) and other cytokines in vaginal secretions at 24-month follow-up. | 24-month follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04098744 -
Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
|
Phase 2 | |
Completed |
NCT04083196 -
A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years
|
Phase 1 | |
Completed |
NCT04191967 -
Thermocoagulation for Treatment of Precancerous Cervical Lesions
|
N/A | |
Withdrawn |
NCT04430907 -
HPV Vaccine in Postpartum Women
|
||
Recruiting |
NCT02593968 -
Yallaferon in Chinese Population
|
Phase 2 | |
Completed |
NCT04711265 -
Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys
|
||
Completed |
NCT02263378 -
A New Supplement for the Immune Response to HPV Infection
|
N/A | |
Completed |
NCT05234112 -
Prevention and Screening Towards Elimination of Cervical Cancer
|
N/A | |
Completed |
NCT04590521 -
HPV Vaccine Immunity in High-risk Women
|
Phase 4 | |
Recruiting |
NCT05829629 -
Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women
|
Phase 1 | |
Recruiting |
NCT06052033 -
Comparison of 5-ALA Photodynamic Therapy and CO2 Laser for Treating Persistent Low-Grade Cervical Lesions With High-Risk HPV Infection
|
N/A | |
Recruiting |
NCT05051852 -
HPV Viral Load in Predicting the Prognosis of LSIL
|
||
Completed |
NCT04155294 -
Re-Evaluation of Annual Cytology Using HPV Testing to Upgrade Prevention in Women Living With HIV
|
||
Active, not recruiting |
NCT06452004 -
Validation of Artificial Intelligence as Decision Support System in VIA (PRESCRIP-TEC)
|
N/A | |
Completed |
NCT06177236 -
Clinic or Self-Sampling for Cervical Cancer Screening
|
N/A | |
Active, not recruiting |
NCT04794660 -
The Study for the "Cervical Cancer Screening and Treatment Algorithms Study Using HPV Testing in Africa"
|
Phase 3 | |
Recruiting |
NCT05509413 -
DEFLAGYN® Vaginal Gel and Spontaneous Remission and Regression of Unclear Cervical Smears and HPV High-risk Infections
|
N/A | |
Recruiting |
NCT06137950 -
Interferon Alpha Therapy for Cervical CINI and HPV Infection
|
Phase 1 | |
Recruiting |
NCT04171505 -
Retrospective Cohort Study of the Effectiveness of the Prophylactic Vaccine Against the Human Papilloma Virus in the Prevention of Recurrence in Women Who Have Received an Excisional Therapy by HSIL / CIN.
|
||
Active, not recruiting |
NCT05524025 -
The SPOT-HPV Study
|